U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07302477) titled 'Human Milk Oligosaccharides (HMOs) - Post Marketing Study on Infants (NeHMO)' on Dec. 11.
Brief Summary: Human milk oligosaccharides (HMOs) represent the third largest solid component of breast milk. Technology advancements made it possible to supplement infant formulas with HMOs (2'FL, LNnT). Two published RCTs have demonstrated that infant formulas supplemented with 2'FL or 2'FL+LNnT are safe, well-tolerated, support normal grow, and may support healthy GI function and confer immune benefits. The performance of HMOs-supplemented formulas assessed in a real-world setting is complementary to previously conducted RCTs conducted in hi...